Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2022-11-24 Regulatory Filings
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Application for quotation of securities 20 pages 330.7KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, dates of issue, and references to previous announcements such as Appendix 3B. This form is a regulatory filing used to notify the exchange and the market about new securities being quoted. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement since it contains substantive information about the securities issuance and quotation application. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-11-24 English
Listed Options Information 2 pages 93.2KB
Major Shareholding Notification Classification · 95% confidence The document is a short announcement dated 25 November 2022 from Biotron Limited addressed to the ASX Limited. It contains a list of the Top 20 Option Holders and a Distribution Schedule for listed options expiring in 2024. The document is only 2242 characters long and does not contain any financial statements, detailed analysis, or report content. It is an announcement of shareholding distribution related to options, not a full report or regulatory filing with financial data. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or details in significant share ownership levels or option holdings. The document is not a full report, nor a certification or proxy material, so MRQ is the best fit with high confidence.
2022-11-24 English
Cleansing Notice 1 page 97.1KB
Capital/Financing Update Classification · 95% confidence The document is a notice from Biotron Limited regarding the issuance of new shares and options under a rights issue and placement, including compliance statements under the Corporations Act 2001. It details the number of shares and options issued, the issue price, and confirms compliance with relevant legal provisions. This is an update on the company's capital raising activities and share issuance, not a full financial report or earnings release. The document length is short (1819 characters) and it is a formal announcement of a capital/financing event. Therefore, it fits the category of Capital/Financing Update (CAP).
2022-11-24 English
Supplementary Prospectus 6 pages 144.6KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Supplementary Prospectus' and is intended to amend and supplement a previously issued Prospectus dated 26 October 2022. It details an additional offer of shares and options, amendments to the capital structure, use of funds, pro-forma balance sheet, payments to underwriters, and other related information. The document is lodged with the Australian Securities and Investments Commission (ASIC) and relates to fundraising activities through share issuance. It is not a full annual or interim report, audit report, earnings release, or management discussion. It is not a proxy solicitation or AGM material. The content focuses on capital raising and changes to the offer terms, which aligns with a Capital/Financing Update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-11-23 English
Rights Issue Closed 2 pages 179.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Biotron Limited regarding the closure of a renounceable rights issue and a follow-on placement, detailing the amounts raised, the number of shares and options issued, and the intended use of proceeds. It is a financing update about capital raising activities, not a full financial report or earnings release. The document length is 4255 characters, which is relatively short and focused on capital raising details. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-11-23 English
Proposed issue of securities - BIT 6 pages 30.5KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Biotron Limited regarding a proposed issue of securities, including details about the number and type of securities to be issued, issue price, conditions, fees, and purpose of the issue. It is structured as a formal notification to the ASX (Australian Securities Exchange) about a placement or other type of securities issuance. There are no financial statements, management discussion, or detailed financial results included. The content focuses on capital raising activities and issuance details, which aligns with a Capital/Financing Update. The document length is sufficient and contains substantive details about the securities issuance, not merely a brief notice or report publication announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-11-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.